Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

May 28, 2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
May 27, 2026

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
May 19, 2026

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
May 13, 2026

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
April 30, 2026

Immunic to Participate in Investor and Medical Conferences in May
April 28, 2026

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
April 23, 2026

Immunic, Inc. Announces 1-for-10 Reverse Stock Split
April 9, 2026

Immunic to Participate in Scientific and Medical Conferences in April
April 1, 2026

Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 31, 2026

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
March 10, 2026

Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
March 3, 2026

Immunic to Participate in Investor Conferences in March
February 26, 2026

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
February 17, 2026

Immunic Announces Closing of Oversubscribed Private Placement Financing
February 13, 2026

Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
February 4, 2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
January 7, 2026

Immunic Highlights 2025 Accomplishments and Upcoming Milestones
November 26, 2025

Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
November 13, 2025

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
October 29, 2025

Immunic to Participate in Industry and Investor Conferences in November
October 1, 2025

Immunic to Participate in Scientific and Investor Conferences in October
September 25, 2025

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
September 9, 2025

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
September 4, 2025

Immunic to Participate in Investor and Scientific Conferences in September
August 7, 2025

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
June 24, 2025

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
June 5, 2025

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
June 3, 2025

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
June 2, 2025

Immunic to Participate in Investor, Scientific and Industry Conferences in June
May 29, 2025

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
May 28, 2025

Immunic, Inc. Announces Proposed Public Offering
May 2, 2025

Immunic to Participate in Scientific and Industry Conferences in May
April 30, 2025

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
April 10, 2025

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
April 9, 2025

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
April 1, 2025

Immunic, Inc. to Participate in Scientific and Industry Conferences in April
March 3, 2025

Immunic to Participate in Scientific and Investor Conferences in March
February 26, 2025

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
February 20, 2025

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
February 4, 2025

Immunic to Participate in Investor and Scientific Conferences in February
January 7, 2025

Immunic Highlights 2024 Accomplishments and Upcoming Milestones
November 26, 2024

Immunic, Inc. to Participate in Investor Conference in December
November 13, 2024

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
November 7, 2024

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 31, 2024

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
October 29, 2024

Immunic to Participate in Industry, Scientific and Investor Conferences in November
October 22, 2024

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
September 18, 2024

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
September 4, 2024

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
August 28, 2024

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
August 8, 2024

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 1, 2024

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
July 24, 2024

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
July 9, 2024

Immunic Appoints Jason Tardio as Chief Operating Officer and President
May 28, 2024

Immunic to Participate in Industry and Scientific Conferences in June
May 8, 2024

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 6, 2024

Immunic to Participate in Investor and Scientific Conferences in May
May 1, 2024

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
April 30, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
April 4, 2024

Immunic to Host MS R&D Day and Participate in Investor Conferences in April
March 20, 2024

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
March 7, 2024

Immunic to Participate in Investor and Scientific Conferences in March
February 29, 2024

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
February 22, 2024

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
February 15, 2024

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 1, 2024

Immunic to Participate in Investor and Scientific Conferences in February
January 5, 2024

Immunic Highlights 2023 Accomplishments and Upcoming Milestones
January 5, 2024

Immunic, Inc. Announces Private Placement of up to $240 Million
November 21, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
November 14, 2023

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 7, 2023

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
November 2, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
October 26, 2023

Immunic to Participate in Scientific and Industry Conferences in November
October 16, 2023

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
October 15, 2023

Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
October 11, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
October 9, 2023

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
October 4, 2023

Immunic to Participate in Scientific Conferences in October
September 6, 2023

Immunic to Participate in Industry and Investor Conferences in September
August 17, 2023

Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
August 3, 2023

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 1, 2023

Immunic to Participate in Investor and Scientific Conferences in August
July 27, 2023

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
June 29, 2023

Immunic to Participate in Scientific and Investor Conferences in July
May 30, 2023

Immunic to Participate in Scientific and Investor Conferences in June
May 17, 2023

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 11, 2023

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
May 6, 2023

Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
May 4, 2023

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
April 27, 2023

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
April 26, 2023

Immunic to Participate in Investor and Scientific Conferences in May
April 5, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
March 2, 2023

Immunic to Participate in Investor and Scientific Conferences in March
February 23, 2023

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
February 22, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
February 16, 2023

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
February 9, 2023

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
January 25, 2023

Immunic to Participate in Scientific and Investor Conferences in February
November 17, 2022

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

Show per page